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CC BY-NC-ND license (http://creativeBackground/Purpose: This study aimed to evaluate the expression of b-catenin and its down-
stream target glutamine synthetase (GS) in hepatoblastoma (HB), and to evaluate the use of
these two markers for diagnosing HB.
Methods: Eighteen untreated HBs and 22 HBs resected after neoadjuvant chemotherapy were
analyzed using b-catenin and GS immunostaining.
Results: We detected nuclear b-catenin immunostaining in nearly all untreated HBs, including
in fetal and embryonal epithelial components and in mesenchymal elements. We also observed
diffuse GS expression in the epithelial component; however, it was frequently absent in embry-
onal and mesenchymal areas. In HBs resected after neoadjuvant chemotherapy, we recognized
four histological patterns: fetal, hepatocellular-carcinoma-like, clear-cell, and normal-liver-
like. All these patterns displayed diffuse GS expression. Fetal pattern showed diffuse nuclear
b-catenin immunostaining. Nuclear b-catenin immunostaining was weak in the hepatocellular-
carcinoma-like and clear-cell patterns. In normal-liver-like area, b-catenin expression was only
located in the cell membrane.
Conclusion: The results suggest that nuclear b-catenin expression and diffuse GS immunostain-
ing are the hallmarks of HB. Although epithelial and mesenchymal components of HB display
nuclear b-catenin staining, this expression is attenuated following chemotherapy-induced cell
maturation. GS immunostaining is especially useful for the assessment of section margins after
neoadjuvant chemotherapy.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).ave no conflicts of interest relevant to this article.
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Hepatoblastoma (HB) is the most common malignant liver
tumor type in childhood, accounting for 66% of malignant
liver neoplasms in pediatric and adolescent populations.1,2
HB is associated with inherited cancer syndrome familial
adenomatous polyposis and BeckwitheWiedemann syn-
drome but not associated with viral hepatitis.3,4 The overall
survival for patients with HB has increased from approxi-
mately 30e80%, largely because of the introduction of
cisplatin-containing neoadjuvant chemotherapy regimens.5
Preoperative chemotherapy reduces tumor size, thereby
allowing the safe removal of many initially unresectable
tumors.6 Liver transplantation is another factor that has
improved patient survival in children with unresectable
tumors.7
HB is characterized by the proliferation of fetal or
embryonal liver-like cells. Mixed epithelial and mesen-
chymal HBs contain a mesenchymal component. In previous
studies, the histomorphology of HBs markedly changed in
response to neoadjuvant chemotherapy.8,9 Two-thirds of
treated HBs display areas of cytoarchitectural differentia-
tion mimicking nontumorous liver parenchyma. Identifying
the maturation part of a tumor can be problematic, espe-
cially when assessing the section margin.
Activation mutations in b-catenin frequently occur in
HB.10,11 Previous studies have identified nuclear b-catenin
expression in most, if not all, untreated HB cases.10,12
Mutation of the b-catenin gene results in stabilization and
translocation of b-catenin into the nucleus, where it can
serve as a transcriptional factor through binding with high-
mobility group box factors of the T-cell factor/lymphoid-
enhancing factor family.13 Glutamine synthetase (GS) is a
downstream target of the Wnt/b-catenin pathway.14 GS
immunostaining is used increasingly in liver tumor diag-
nosis, especially well-differentiated hepatocellular carci-
noma (HCC), focal nodular hyperplasia, and b-catenin-
mutated hepatocellular adenoma.15e17 Although in-
vestigators have identified GS expression in untreated HB,18
its expression in chemotherapy-treated HB and its role in
HB diagnosis have yet to be fully elucidated.
In this study, we evaluated b-catenin and GS immuno-
staining in 18 untreated HB and 22 HB samples obtained
from surgical resection specimens after neoadjuvant
chemotherapy. Our results showed that b-catenin immu-
nostaining and GS immunostaining have complementary
roles in HB diagnosis.
Methods
Clinical specimens
Liver open biopsy or surgically resected HB specimens
retrieved from the Department of Pathology, National
Taiwan University Hospital, Taiwan, Taipei, were evaluated.
Thirteen untreated HB specimens were obtained by open
biopsy and five untreated HB specimens were surgically
resected. All 22 HB specimens were surgically resected tu-
mors obtained after neoadjuvant chemotherapy. They
included nine pairs of pretreated and post-treated speci-
mens. The diagnoses of all cases were confirmed by two liverPlease cite this article in press as: Huang W-J, et al., Complementar
diagnosis of chemotherapy-treated and untreated hepatoblastoma,
dx.doi.org/10.1016/j.jfma.2016.09.013pathologists (Y.M.J. and J.H.T.). The study protocol was
approved by the Research Ethics Committee of National
Taiwan University Hospital, and all specimens were
rendered anonymous and evaluated in a blinded manner.
Immunohistochemistry
Tissue sections (5mm)weredewaxedand rehydrated.Antigen
retrieval was performed by incubating the slides in 0.01M
citric acid buffer at 100C for 10 minutes. After blocking with
3% hydrogen peroxide and 5% fetal bovine serum, the slides
were incubated with a mouse anti-GS antibody (clone GS-6,
dilution 1:150; Millipore, Bedford, MA, USA) or an anti-b-
catenin antibody (dilution 1:80, BD Transduction Labora-
tories, Lexington, KY, USA) at 4C overnight. The slides were
incubated with a polymer-horseradish peroxidase reagent
(BioGenex, San Ramon, CA, USA), and peroxidase activitywas
visualized using a diaminobenzidine tetrahydroxychloride
solution (BioGenex). The sections were counterstained with
hematoxylin. For negative controls, theprimary antibodywas
replaced with 5% fetal bovine serum.
Results
Sixteen untreated HBs were composed of pure epithelial
components, and two contained mixed epithelial and
mesenchymal elements. In five tumors, the epithelial
components were the fetal subtype (Figure 1A). The other
13 tumors displayed a combination of the fetal and
embryonal cell types (Figure 1D). The mesenchymal
component in one tumor was composed of undifferentiated
spindle cells (Figure 1G). We identified osteoid production
in one tumor.
In the post-treatment group, 14 tumors showed signifi-
cant treatment effects, as defined by necrosis of tumor
cells, fibrosis, foreign body reaction, and hemosiderin
deposition in > 50% of the tumor areas. In one tumor, we
observed fibrous tissue and mature bone only, and total
eradication of the tumor cells.
In the eight HBs without an evident treatment effect,
cell morphology was similar to untreated HBs. In six tumors,
the predominant component was fetal-type epithelial cells
(Figure 2A). One tumor contained a malignant mesen-
chymal component. In one tumor, the cells contained
abundant eosinophilic cytoplasm and were arranged in
thick trabeculae, mimicking HCC. We classified them as
HCC-like pattern (Figure 2D), according to the descriptions
of a previous report.8
In the HBs with significant treatment effects, all tumors
showed variable degrees of cytoarchitectural differentia-
tion. In five tumors, we identified residual fetal-type
epithelial cells. No case showed residual embryonal-type
epithelial cells or malignant mesenchymal components.
According to the degree of cytoarchitectural differentia-
tion, we classified the epithelial cells into three types. The
fetal type consisted of epithelial cells resembling fetal-
type epithelial cells in untreated HB, characterized by
medium-sized tumor cells with clear or eosinophilic cyto-
plasm arranged in cords or slender plates with intervening
sinusoids. The clear-cell type consisted of mature-looking
hepatocytes with abundant clear cytoplasm, arranged iny roles of b-catenin and glutamine synthetase immunostaining in
Journal of the Formosan Medical Association (2016), http://
Figure 1 Histological patterns and b-catenin and glutamine synthetase (GS) expression in untreated hepatoblastoma (HB). (AeC)
A pure fetal-type HB with diffuse nuclear b-catenin expression and diffuse GS expression. (DeF) A HB containing mixed fetal and
embryonal cell types. Nuclear b-catenin was identifiable in both fetal and embryonal areas (E). GS was expressed in the fetal area
but not in the embryonal area (F). (GeI) A HB with mixed epithelial and mesenchymal elements. Nuclear b-catenin was expressed
in both epithelial and mesenchymal areas (H). GS was expressed in the epithelial area but not in the mesenchymal area (I).
(Original magnification: 400).
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+ MODELtrabeculae of one or two layers (Figure 2G). The normal-
liver-like type consisted of cells resembling non-
neoplastic hepatocytes, with abundant eosinophilic cyto-
plasm and small, round uniform nuclei, arranged in
trabeculae of one or two layers (Figure 2J). We classified
three tumors as pure fetal type, three as pure clear-cell
type, and four as pure normal-liver-like type. The other
tumors consisted of mixtures of fetal, clear, and normal-
liver-like cell types in various combinations.
We observed membranous b-catenin staining in the
nontumorous hepatocytes, bile ducts, and epithelial com-
ponents of tumor cells. In the pretreatment group, 17 tu-
mors displayed strong nuclear b-catenin expression in
> 50% of their cells (Figures 1B, 1E, and 1H). Both epithelial
and mesenchymal components showed nuclear b-catenin
staining (Figure 1H). In the one tumor without diffuse nu-
clear b-catenin staining, we observed nuclear b-catenin
expression in w5% of tumor cells. In the post-treatment
group, we identified diffuse or scattered nuclear b-cat-
enin expression in the fetal-type epithelial cells (Figure 2B)
and in the malignant mesenchymal component. In the
tumor containing HCC-like cells, we identified nuclear b-
catenin expression in 5e10% of the cells (Figure 2E). We
also observed nuclear b-catenin staining in the clear-cell-
type epithelial cells; however, it was generally weak and
scattered (Figure 2H). The normal-liver-like cells displayed
membranous b-catenin staining only (Figure 2K).Please cite this article in press as: Huang W-J, et al., Complementar
diagnosis of chemotherapy-treated and untreated hepatoblastoma,
dx.doi.org/10.1016/j.jfma.2016.09.013The epithelial component of all untreated HBs showed
strong cytoplasmic GS immunostaining (Figures 1C, 1F, and
1I). This staining was typically diffuse but a focal mosaic
patternwas observed inmost cases. Inmore undifferentiated
(embryonal) areas, GS immunostainingwas frequently absent
(Figure 1F). The malignant mesenchymal components were
negative for GS expression (Figure 1I). In the post-treatment
group, all HBs, irrespective of histological pattern, showed
strong GS-positive staining (Figures 2C, 2F, 2I, and 2L). To be
noteworthy, the tumor cells in the normal-liver-like tumor
cells did not display nuclear b-catenin staining but were
diffusely positive for GS (Figures 2Je2L). The fibrous stroma
and the osteocytes in the bony componentswere negative for
GS. The nontumorous liver parenchyma showed a perivenular
pattern, as reported previously.15
Discussion
Following chemotherapy, most HBs show significant
cytoarchitectural maturation and occasionally mimic non-
tumorous liver tissue. The location within or adjacent to
the main tumor mass, and absence of portal areas, are
helpful features for the identification of such parts. How-
ever, their identification can still be problematic, espe-
cially when assessing the section margin.
Two previous reports described the effects of neo-
adjuvant chemotherapy on b-catenin expression in HB, iny roles of b-catenin and glutamine synthetase immunostaining in
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Figure 2 Histological patterns and b-catenin and glutamine synthetase (GS) expression in neoadjuvant chemotherapy-treated
hepatoblastoma (HB). (AeC) A pure fetal-type HB with diffuse nuclear b-catenin expression and mosaic GS expression. (DeF)
Hepatocellular-carcinoma-like pattern. The tumor cells contained abundant eosinophilic cytoplasm and were arranged in thick
trabeculae (D). Nuclear b-catenin expression in a small subset of tumor cells (E). The tumor cells were positive for GS with het-
erogeneity in staining intensity (F). (GeI) Clear-cell pattern. The tumor cells contained clear cytoplasm and small regular nuclei
(G). Nuclear b-catenin staining was weak and scattered (H). The tumor cells were diffusely positive for GS (I). (JeL) Normal-liver-
like pattern. The tumor cells contained abundant eosinophilic cytoplasm and small regular nuclei (J). Cell membranous b-catenin
expression (K). The tumor cells were diffusely positive for GS (L). (Original magnification: 200 for Figure 2D, 400 for others).
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relatively unaffected post-treatment.8,19 By contrast, we
identified that nuclear b-catenin expression was associated
with the tumor cell differentiation status. Strong nuclear
expression was found in all pretreated HBs and fetal-type
cells post-treatment. We observed weak nuclear b-cat-
enin immunostaining in HCC-like and clear-cell types and
negative staining in the normal-liver-like cell type. It is well
known that colon carcinomas harboring APC mutations do
not express nuclear b-catenin homogeneously.20 Nuclear b-
catenin expression is frequently observed in stem-cell-like
cells in invasive front of colorectal cancer but rarely iden-
tified in the differentiated glandular structure.21 Pre-
treated HB more frequently expresses nuclear b-catenin in
more undifferentiated areas (embryonal type) than in morePlease cite this article in press as: Huang W-J, et al., Complementar
diagnosis of chemotherapy-treated and untreated hepatoblastoma,
dx.doi.org/10.1016/j.jfma.2016.09.013differentiated areas (fetal type). These observations and
our findings indicate that multiple factors determine b-
catenin accumulation and that nuclear b-catenin expres-
sion downregulates after cell differentiation. The reason
for discrepancies between our results and those of previous
studies is unclear. Variations in chemotherapy regimens,
immunostaining methods, and histological criteria might
account for some of the differences.
GS is a novel immunohistochemical marker used for
diagnosing liver mass. GS is more frequently expressed in
well-differentiated HCC than in dysplastic nodules.15 In
focal nodular hyperplasia, GS immunostaining shows a
characteristic map-like pattern, which is distinct from im-
munostaining in nontumorous liver parenchyma.16 GS is also
diffusely expressed in b-catenin-mutated hepatocellulary roles of b-catenin and glutamine synthetase immunostaining in
Journal of the Formosan Medical Association (2016), http://
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marker of Wnt/b-catenin pathway activation. However, not
all tumors that express GS also display nuclear b-catenin
expression. For example, although map-like GS expression
occurs in focal nodular hyperplasia, no study has identified
nuclear b-catenin expression in focal nodular hyperplasia
using immunohistochemistry.22 These observations indicate
that low-level activation of b-catenin or other mechanisms
might, therefore, be sufficient to induce GS expression in
liver tumors. According to these observations, we propose
that GS might be a useful marker for identifying residual
tumor cells after neoadjuvant chemotherapy for HB. We
identified that GS is diffusely expressed in the residual
epithelial component after chemotherapy. GS immuno-
staining is most useful for identifying normal-liver-like
tumor cells, which are difficult to differentiate from non-
tumorous liver parenchyma and negative for nuclear b-
catenin expression.
In conclusion, we identified frequent nuclear b-catenin
staining and diffuse GS staining in HB. Nuclear b-catenin
expression is displayed in both epithelial and mesenchymal
components, but is frequently absent in differentiated
tumor cells post-chemotherapy. GS is expressed in epithe-
lial cells and is most useful for identifying residual tumor
cells after chemotherapy, especially when evaluating sec-
tion margin status.References
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